AKBA - アケビア・セラピュ―ティクス (Akebia Therapeutics Inc.) アケビア・セラピュ―ティクス

 AKBAのチャート


 AKBAの企業情報

symbol AKBA
会社名 Akebia Therapeutics Inc (アケビア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アケビ・セェラァピュゥーティィクス(Akebia Therapeutics Inc.)はバイオ医薬品企業である。同社は低酸素誘導性因子(HIF)の生物学に基づいた治療薬の開発と商品化に従事する。同社の主力な候補製品のバダデュスタットは、慢性腎疾患(CKD)における貧血の治療に適応される。同社は経口療法におけるバダダスタットの開発を行う。バダスタットは、CKDの貧血の治療のためのフェーズⅢ開発におけるHIF-プロリルヒドロキシラーゼ(HIF-PH)阻害剤である。また、同社は疾患を標的とするHIFベースの候補製品のポートフォリオの開発に従事する。同社のポートフォリオは、社内で開発された候補製品のAKB-6899、ライセンス取得済みの候補製品のAKB-5169を含む。AKB-5169は、炎症性腸疾患(IBD)のための経口治療として開発中の前臨床化合物である。   アケビア・セラピュ―ティクスは米国のバイオ医薬品会社。低酸素誘導因子、HIF、生物学と腎臓病の患者用製品の商品化に基づく独自の治療法の開発に焦点を当てる。 「HIF」は体内で赤血球の生産と貧血を治療する。「AKB-6548」は一日一回の経口療法、「AKB-6548」は安定的にヘモグロビンレベルを上昇させる。本社はマサチュ―セッツ州ケンブリッジ。   Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The Company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
本社所在地 245 First Street Suite 1100 Cambridge MA 02142 USA
代表者氏名 Muneer A. Satter ムネア・サッター
代表者役職名 Independent Chairman of the Board
電話番号 +1 617-871-2098
設立年月日 39114
市場名 NASDAQ National Market System
ipoyear 2014年
従業員数 114人
url www.akebia.com
nasdaq_url https://www.nasdaq.com/symbol/akba
adr_tso
EBITDA EBITDA(百万ドル) -72.19200
終値(lastsale) 8.59
時価総額(marketcap) 490029976.17
時価総額 時価総額(百万ドル) 484.88320
売上高 売上高(百万ドル) 223.32200
企業価値(EV) 企業価値(EV)(百万ドル) 82.76020
当期純利益 当期純利益(百万ドル) -68.34100
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akebia Therapeutics Inc revenues increased 92% to $94.7M. Net loss decreased 13% to $57.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Stock-based Compensation in R&D decrease of 72% to $1.4M (expense) Interest income increase from $1M to $2.6M (income) Other Non Rec.

 AKBAのテクニカル分析


 AKBAのニュース

   REV Stock Moves Amid Revlon Bankruptcy, Short Squeeze Hopes  2022/07/01 16:25:29 InvestorPlace
Source: Casimiro PT / Shutterstock.com Revlon (NYSE: REV ) stock is on the move Friday as the volatility surrounding the meme stock continues following its bankruptcy announcement. Revlon has been a hot name among retailers recently as investors hold out hopes for a short squeeze of the stock. The interest in REV stock started to ramp up last month when the company announced a bankruptcy filing. Fintel even listed REV stock as one of the top companies with short-squeeze potential for this week. It’s not just short squeeze hopes that have REV stock on the move. There’s also been rumors circulating that another company may swoop in and buy the failing fashion product maker . While there’s no official word on that, it’s still been keeping investors excited these last couple of weeks. Of course, there is a reason that REV stock is seeing so much price action today. The stock has been experiencing heavy trading ever since markets opened. As a result, some 20 million shares have changed hands as of this writing.
   U.S Stocks Turn Lower; Dow Tumbles Over 100 Points  2022/07/01 16:20:16 Benzinga
U.S. stocks turned lower midway through trading, with the Dow Jones dropping more than 100 points on Friday. The Dow traded down 0.44% to 30,639.41 while the NASDAQ fell 0.59% to 10,936.46. The S&P also fell, dropping, 0.46% to 3,767.81. Also check this: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Utilities shares rose by 1.4% on Friday. Meanwhile, top gainers in the sector included American Water Works Company, Inc. (NYSE: AWK ), up 3% and Atlantica Sustainable Infrastructure plc (NASDAQ: AY ) up 3%. In trading on Friday, energy shares fell by 1.6%. Top Headline The ISM manufacturing index fell to 53 for June from 56.1 in May. Analysts, however, were expecting a reading of 54.9. Equities Trading UP VerifyMe, Inc. (NASDAQ: VRME ) shares shot up 21% to $2.3807 after the company announced liquidation of the G3 VRM Acquisition SPAC and initiated a new share repurchase program. Shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA ) got a boost, shooting 18% to $0.4181 after the company executed an agreement to terminate its vadadustat Collaboration and License Agreements with Otsuka …
   Why Is Akebia Therapeutics (AKBA) Stock Up 14% Today?  2022/07/01 16:02:19 InvestorPlace
Source: Shutterstock Akebia Therapeutics (NASDAQ: AKBA ) stock is taking off on Friday after the kidney treatment company revealed the return of rights for vadadustat . Vadadustat is Akebia Therapeutics’ “investigational oral hypoxia-inducible factor prolyl hydroxylase inhibitor.” Today’s news has Otsuka returning the rights for the treatment in the U.S., Europe, China, Russia, Canada, Australia, the Middle East, as well as certain other territories. It’s worth noting that with this return of rights, Otsuka is paying a $55 million fee to Akebia Therapeutics. To go along with that, Otsuka is also transferring the marketing authorization application (MAA) in Europe to the company. 7 Butchered Tech Stocks to Buy and Hold John Butler, CEO of Akebia Therapeutics, said this in a press release. “We continue to believe in the potential of vadadustat as an oral treatment for patients with anemia due to chronic kidney disease, and we are pleased to be regaining the full rights to the product in these important markets.” News of Akebia Therapeutics regaining rights to vadadustat also has AKBA seeing heavy trading today.
   Why U.S. Stocks Are Trading Higher, Manufacturing Report And More  2022/07/01 14:05:53 Benzinga
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 100 points on Friday. The Dow traded up 0.38% to 30,893.82 while the NASDAQ rose 0.50% to 11,084.33. The S&P also rose, gaining, 0.46% to 3,802.86. Also check this: RH, Walgreens And 3 Stocks To Watch Heading Into Thursday Leading and Lagging Sectors Consumer discretionary shares rose by 1.7% on Friday. Meanwhile, top gainers in the sector included Faraday Future Intelligent Electric Inc. (NASDAQ: FFIE ), up 16% and LightInTheBox Holding Co., Ltd. (NYSE: LITB ) up 10%. In trading on Friday, materials shares fell by 0.4%. Top Headline The ISM manufacturing index fell to 53 for June from 56.1 in May. Analysts, however, were expecting a reading of 54.9. Equities Trading UP VerifyMe, Inc. (NASDAQ: VRME ) shares shot up 33% to $2.61 after the company announced liquidation of the G3 VRM Acquisition SPAC and initiated a new share repurchase program. Shares of Akebia Therapeutics, Inc. (NASDAQ: AKBA ) got a boost, shooting 27% to $0.45 after the company executed an agreement to terminate its vadadustat Collaboration and License Agreements with Otsuka Pharmaceutical.
   Akebia Therapeutics And 20 Stocks Moving Premarket  2022/07/01 10:56:18 Benzinga
Gainers Quoin Pharmaceuticals, Ltd. (NASDAQ: QNRX ) rose 83.2% to $0.8250 in pre-market trading after dropping 10% on Thursday. Fast Radius, Inc. (NASDAQ: FSRD ) rose 57.2% to $0.9900 in pre-market trading after jumping over 37% on Thursday. Fast Radius recently appointed Pat McCusker as President, Interim CFO and John Nanry as COO. Akebia Therapeutics, Inc. (NASDAQ: AKBA ) rose 33.1% to $0.4701 in pre-market trading after the company executed an agreement to terminate its vadadustat collaboration and license agreements with Otsuka Pharmaceutical. Shift Technologies, Inc. (NASDAQ: SFT ) rose 27.7% to $0.86 in pre-market trading after declining around 7% on Thursday. ECMOHO Limited (NASDAQ: MOHO ) rose 27.5% to $0.2093 in pre-market trading after dropping over 4% on Thursday. AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX ) rose 22.8% to $0.30 in pre-market trading. OceanPal Inc. (NASDAQ: OP ) rose 15.5% to $0.55 in pre-market trading. OceanPal recently announced entry into agreement to acquire capesize dry bulk vessel.
   Akebia Q1 2022 Earnings Preview  2022/05/08 21:35:00 Seeking Alpha
Akebia (AKBA) is scheduled to announce Q1 earnings results on Monday, May 9th, after market close.The consensus EPS Estimate is -$0.29 and the consensus Revenue Estimate is $44.22M…
   ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important May 13 Deadline in Securities Class Action - AKBA  2022/04/29 21:36:00 Benzinga
NEW YORK , April 29, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA ) between June 28, 2018 and September 2, 2020 , inclusive (the "Class Period"), of the important May 13, 2022 lead plaintiff deadline . SO WHAT: If you purchased Akebia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on … Full story available on Benzinga.com
   AKBA INVESTOR NOTICE: ROSEN, TRUSTED AND TOP RANKED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AKBA  2022/04/20 17:19:00 Benzinga
NEW YORK , April 20, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA ) between June 28, 2018 and September 2, 2020 , inclusive (the "Class Period"), of the important May 13, 2022 lead plaintiff deadline . SO WHAT: If you purchased Akebia securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Akebia class action, go to https://rosenlegal.com/submit-form/?case_id=4028 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information … Full story available on Benzinga.com
   The Klein Law Firm Announces a Lead Plaintiff Deadline of May 13, 2022 in the Class Action Filed on Behalf of Akebia Therapeutics, Inc. Shareholders  2022/04/20 14:06:00 iCrowdNewswire
The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Akebia Therapeutics, Inc. alleging that the Company violated federal securities laws. Class Period: June 28, 2018 to September 2, 2020Lead Plaintiff Deadline: May 13, 2022No obligation or […]
   ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Akebia Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AKBA  2022/04/18 18:02:00 GlobeNewswire
NEW YORK, April 18, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the “Class Period”), of the important May 13, 2022 lead plaintiff deadline .
   See Why Does HC Wainwright Maintain Neutral On Akebia Stock  2022/04/07 18:38:16 Benzinga
Akebia Therapeutics Inc (NASDAQ: AKBA ) announced three poster presentations at the National Kidney Foundation (NKF) Spring Clinical Meetings 2022. Poster data demonstrated that overall, vadadustat did not increase the risk of dialysis access thrombotic events (TE) compared to darbepoetin alfa (DA) among 1,947 patients who received vadadustat and 1,955 patients who received DA. Initial presentation at ASN Kidney Week 2021, the number of vascular access site thrombosis during the INNOVATE studies was 34 (1.7%) on vadadustat vs. 41 (2.1%) on DA. Of those, 8 of 34 (23.5%) on vadadustat vs. 16 of 41 (39.0%) on DA were deemed serious. Also Read: FDA Places Partial Hold On Vadadustat … Full story available on Benzinga.com
   FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff  2022/04/07 16:49:30 Benzinga
Battered after a surprising FDA rejection for its lead pipeline program last week, Akebia Therapeutics Inc (NASDAQ: AKBA ) has layoffs that are now on the way. In a filing with the SEC , Akebia said the FDA issued a partial clinical hold on the drug''s pediatric studies. As a result, Akebia will suspend all vadadustat studies in children. According to the filing, Akebia … Full story available on Benzinga.com
   ROSEN, A LEADING LAW FIRM, Encourages Akebia Therapeutics, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important Deadline in Securities Class Action - AKBA  2022/04/06 17:49:00 PR Newswire
NEW YORK, April 6, 2022 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Akebia Therapeutics, Inc. (NASDAQ: AKBA) between June 28, 2018 and September 2, 2020, inclusive (the "Class Period"), of the important May 13, 2022 lead…
   SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Akebia Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - AKBA  2022/04/03 23:39:00 Kwhen Finance
   The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight  2022/04/03 21:33:22 Benzinga
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that moved stocks during the week. Longeveron Inc. (NASDAQ: LGVN ) jumped over 100% after the biopharma announced the publication of positive Phase 1 data for its Lomecel-B in Alzheimer''s disease. Clovis Oncology, Inc. (NASDAQ: CLVS ) also benefited from a positive data readout. On the other hand, Akebia Therapeutics, Inc. (NASDAQ: AKBA ) and Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX ) came under selling pressure due to adverse regulatory tidings. The former''s vadadustat was rejected by the Food and Drug Administration as a treatment option for anemia in chronic kidney disease patients, while the latter''s amyotrophic lateral sclerosis treatment candidate wasn''t recommended for approval by an Adcom panel. Here are the key catalysts for the unfolding week: Conferences The American College of Cardiology, or ACC,''s 71st Annual Scientific Session & Expo: April 2-4, in Washington, …

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アケビア・セラピュ―ティクス AKBA Akebia Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)